Media coverage about Jounce Therapeutics (NASDAQ:JNCE) has trended somewhat positive this week, according to Accern Sentiment. The research firm identifies positive and negative press coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Jounce Therapeutics earned a coverage optimism score of 0.23 on Accern’s scale. Accern also gave media coverage about the company an impact score of 44.7835696477925 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

A number of brokerages have recently issued reports on JNCE. Robert W. Baird restated an “outperform” rating and issued a $30.00 target price on shares of Jounce Therapeutics in a research note on Monday, September 18th. Zacks Investment Research upgraded shares of Jounce Therapeutics from a “hold” rating to a “buy” rating and set a $13.00 target price on the stock in a research note on Friday, August 11th. Finally, Cowen and Company restated a “buy” rating on shares of Jounce Therapeutics in a research note on Friday, June 9th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $23.67.

Shares of Jounce Therapeutics (NASDAQ:JNCE) traded up 1.35% during midday trading on Friday, hitting $14.97. 91,477 shares of the stock were exchanged. The stock’s 50 day moving average is $15.16 and its 200 day moving average is $15.16. Jounce Therapeutics has a 12-month low of $14.41 and a 12-month high of $24.79. The firm has a market cap of $481.35 million and a P/E ratio of 554.44.

Jounce Therapeutics (NASDAQ:JNCE) last issued its quarterly earnings results on Wednesday, August 9th. The company reported ($0.11) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.04. The company had revenue of $20.29 million during the quarter, compared to the consensus estimate of $19.94 million. During the same period last year, the company earned ($7.23) earnings per share. On average, equities research analysts forecast that Jounce Therapeutics will post ($0.62) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Jounce Therapeutics (JNCE) Receiving Somewhat Positive News Coverage, Analysis Shows” was published by Daily Political and is the property of of Daily Political. If you are reading this piece on another publication, it was copied illegally and republished in violation of U.S. & international trademark and copyright legislation. The legal version of this piece can be viewed at

About Jounce Therapeutics

Jounce Therapeutics, Inc is a clinical stage immunotherapy company. The Company is engaged in transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long lasting benefits to patients. Through the use of its Translational Science Platform, Jounce first focuses on specific cell types within tumors to prioritize targets, and then identifies related biomarkers designed to match the right therapy to the right patient.

Insider Buying and Selling by Quarter for Jounce Therapeutics (NASDAQ:JNCE)

Receive News & Ratings for Jounce Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jounce Therapeutics Inc. and related companies with's FREE daily email newsletter.